These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2545342

  • 1. Significant increase in the antibody to Gal alpha 1-3Gal structure in sera of patients with hepatocellular carcinoma after transcatheter arterial embolization.
    Kashiwagi M, Ikeda Y, Iwamori M, Toda G, Nagai Y.
    Cancer Res; 1989 Aug 15; 49(16):4396-401. PubMed ID: 2545342
    [Abstract] [Full Text] [Related]

  • 2. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients.
    Zhou SF, Xie XX, Bin YH, Lan L, Chen F, Luo GR.
    Clin Chim Acta; 2006 Apr 15; 366(1-2):274-80. PubMed ID: 16356486
    [Abstract] [Full Text] [Related]

  • 3. Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy.
    Kaneko A, Hayashi N, Tanaka Y, Ito T, Kasahara A, Kubo M, Mukuda T, Fusamoto H, Kamada T.
    Am J Gastroenterol; 1992 Aug 15; 87(8):1014-7. PubMed ID: 1322635
    [Abstract] [Full Text] [Related]

  • 4. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I.
    Clin Biochem; 2009 Apr 15; 42(6):455-61. PubMed ID: 19063876
    [Abstract] [Full Text] [Related]

  • 5. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.
    Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA.
    Cancer Res; 2004 Oct 15; 64(20):7329-35. PubMed ID: 15492253
    [Abstract] [Full Text] [Related]

  • 6. Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury.
    Moody DE, Loury DN, Hammock BD, Ruebner BH, Cullen JM, Hillman JH, Hillman DW, Rao MS, London WT, Hann HW.
    Cancer Epidemiol Biomarkers Prev; 1992 Oct 15; 1(5):395-403. PubMed ID: 1339049
    [Abstract] [Full Text] [Related]

  • 7. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
    Chen DS.
    Princess Takamatsu Symp; 1995 Oct 15; 25():27-32. PubMed ID: 8875606
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
    Kitaoka S, Shiota G, Kawasaki H.
    Hepatogastroenterology; 2003 Oct 15; 50(53):1569-74. PubMed ID: 14571788
    [Abstract] [Full Text] [Related]

  • 9. [Changes in ketone body ratio and levels of pyruvate and lactate in arterial blood of patients with hepatocellular carcinoma after transcatheter arterial embolization].
    Mizobuchi N, Kuwao F, Takeda I, Takemura T, Morita S, Horimi T, Takahashi I.
    Rinsho Byori; 1990 Jul 15; 38(7):825-9. PubMed ID: 2169547
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.
    Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, Tateishi R, Imamura M, Hamamura K, Teratani T, Shiina S, Ishikawa T, Omata M.
    Liver Int; 2004 Dec 15; 24(6):625-9. PubMed ID: 15566514
    [Abstract] [Full Text] [Related]

  • 11. Serum hepatocyte growth factor levels in liver diseases: clinical implications.
    Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T.
    Hepatology; 1995 Jan 15; 21(1):106-12. PubMed ID: 7806142
    [Abstract] [Full Text] [Related]

  • 12. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
    Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Torigoe T, Sato N, Watanabe N.
    Autoimmunity; 2005 Sep 15; 38(6):445-8. PubMed ID: 16278150
    [Abstract] [Full Text] [Related]

  • 13. Detection and characterization of antibody to liver cell membrane in sera from patients with chronic active liver diseases.
    Tsuji T, Araki K, Naito K, Inoue J, Nacashima H.
    Acta Med Okayama; 1979 Feb 15; 33(1):61-6. PubMed ID: 220848
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis Be antigen and antibody in chronic liver diseases and hepatocellular carcinoma.
    Chen DS, Sung JL, Lai MY.
    Hepatogastroenterology; 1981 Dec 15; 28(6):288-91. PubMed ID: 6284625
    [Abstract] [Full Text] [Related]

  • 15. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.
    Yamashita F, Tanaka M, Satomura S, Tanikawa K.
    Eur J Gastroenterol Hepatol; 1995 Jul 15; 7(7):627-33. PubMed ID: 8590157
    [Abstract] [Full Text] [Related]

  • 16. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
    Shimizu Y, Minemura M, Tsukishiro T, Kashii Y, Miyamoto M, Nishimori H, Higuchi K, Watanabe A.
    Hepatology; 1995 Aug 15; 22(2):525-31. PubMed ID: 7543436
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum interleukin 6 as a predicator of the therapeutic effect and adverse reactions after transcatheter arterial embolization.
    Yamazaki H, Nishimoto N, Oi H, Matsushita M, Ogata A, Shima Y, Inoue T, Tang JT, Yoshizaki K, Kishimoto T.
    Cytokine; 1995 Feb 15; 7(2):191-5. PubMed ID: 7780039
    [Abstract] [Full Text] [Related]

  • 19. Definition of tumor-associated antigens in hepatocellular carcinoma.
    Stenner-Liewen F, Luo G, Sahin U, Tureci O, Koslovski M, Kautz I, Liewen H, Pfreundschuh M.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 15; 9(3):285-90. PubMed ID: 10750667
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.